See the latest news and media coverage for Modus Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Swedish biotechnology company developing sevuparin
modustx.comLast updated
In short: Modus Therapeutics progressed its clinical and preclinical research for sevuparin while securing significant funding through several rights issues.
The AGM resolved no dividend, discharged board and MD, re-elected Viktor Drvota, elected Pernilla Sandwall and Sofi Eriksson, approved SEK110,000 fees, reappointed Ernst & Young, and authorized share issues.
The report highlights disciplined execution and progress in the Phase IIa study for sevuparin, with proof-of-concept readout expected by end of 2026.
The exercise rate is 94.8%, yielding approximately SEK 9.5 million before costs and 18% dilution.
The meeting occurs on May 28, 2026, in Stockholm. Proposals include board elections, no dividend, and share issue authorization.
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive...
Aktieägarna i Modus Therapeutics Holding AB (publ), kallas härmed till årsstämma tisdagen den 20 maj 2025 klockan 11.00 i Advokatfirman Vinges lokaler, Smålandsgatan 20, i...
STOCKHOLM – 14 November 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-September 2025. The full report is available on the...
Proof-of-concept phase begins with first patient enrolled...
Track Modus Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.